GE23077 binds to the RNA polymerase 'i' and 'i+1' sites and prevents the binding of initiating nucleotides.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Ho, Mary X
Ebright, Katherine Y
Ebright, Yon W
Ebright, Richard H
MetadataShow full item record
AbstractUsing a combination of genetic, biochemical, and structural approaches, we show that the cyclic-peptide antibiotic GE23077 (GE) binds directly to the bacterial RNA polymerase (RNAP) active-center 'i' and 'i+1' nucleotide binding sites, preventing the binding of initiating nucleotides, and thereby preventing transcription initiation. The target-based resistance spectrum for GE is unusually small, reflecting the fact that the GE binding site on RNAP includes residues of the RNAP active center that cannot be substituted without loss of RNAP activity. The GE binding site on RNAP is different from the rifamycin binding site. Accordingly, GE and rifamycins do not exhibit cross-resistance, and GE and a rifamycin can bind simultaneously to RNAP. The GE binding site on RNAP is immediately adjacent to the rifamycin binding site. Accordingly, covalent linkage of GE to a rifamycin provides a bipartite inhibitor having very high potency and very low susceptibility to target-based resistance. DOI: http://dx.doi.org/10.7554/eLife.02450.001.
CitationGE23077 binds to the RNA polymerase 'i' and 'i+1' sites and prevents the binding of initiating nucleotides. 2014, 3:e02450 Elife
AffiliationDept. Micribial Derugs, Helmholtz Centre for infection research, Inhoffenstr. 7, D-38124 Braunschweig, Germany.
The following license files are associated with this item:
- Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase.
- Authors: Sarubbi E, Monti F, Corti E, Miele A, Selva E
- Issue date: 2004 Aug
- Still looking for the magic spot: the crystallographically defined binding site for ppGpp on RNA polymerase is unlikely to be responsible for rRNA transcription regulation.
- Authors: Vrentas CE, Gaal T, Berkmen MB, Rutherford ST, Haugen SP, Vassylyev DG, Ross W, Gourse RL
- Issue date: 2008 Mar 21
- Transcription inhibition by the depsipeptide antibiotic salinamide A.
- Authors: Degen D, Feng Y, Zhang Y, Ebright KY, Ebright YW, Gigliotti M, Vahedian-Movahed H, Mandal S, Talaue M, Connell N, Arnold E, Fenical W, Ebright RH
- Issue date: 2014 Apr 30
- Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins.
- Authors: Artsimovitch I, Vassylyeva MN, Svetlov D, Svetlov V, Perederina A, Igarashi N, Matsugaki N, Wakatsuki S, Tahirov TH, Vassylyev DG
- Issue date: 2005 Aug 12
- Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
- Authors: Gill SK, Garcia GA
- Issue date: 2011 Sep